PRELUDE THERAPEUTICS INC's ticker is PRLD and the CUSIP is 74065P101. A total of 63 filers reported holding PRELUDE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,576,762 | -31.2% | 510,279 | +0.2% | 0.00% | 0.0% |
| Q2 2023 | $2,292,255 | -21.8% | 509,390 | -1.0% | 0.00% | 0.0% |
| Q1 2023 | $2,932,924 | -5.7% | 514,548 | -0.1% | 0.00% | 0.0% |
| Q4 2022 | $3,110,425 | -8.3% | 514,971 | +0.3% | 0.00% | 0.0% |
| Q3 2022 | $3,393,000 | +35.8% | 513,293 | +7.3% | 0.00% | 0.0% |
| Q2 2022 | $2,498,000 | -24.9% | 478,525 | -0.7% | 0.00% | 0.0% |
| Q1 2022 | $3,327,000 | -43.0% | 482,119 | +2.8% | 0.00% | -50.0% |
| Q4 2021 | $5,837,000 | -60.4% | 468,797 | -0.7% | 0.00% | -50.0% |
| Q3 2021 | $14,758,000 | +37.4% | 472,246 | +25.9% | 0.00% | +33.3% |
| Q2 2021 | $10,741,000 | -11.8% | 375,166 | +33.4% | 0.00% | -25.0% |
| Q1 2021 | $12,183,000 | -40.1% | 281,164 | -1.1% | 0.00% | -42.9% |
| Q4 2020 | $20,334,000 | +30.3% | 284,187 | -45.1% | 0.01% | +16.7% |
| Q3 2020 | $15,608,000 | – | 518,011 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 10,039,691 | $52,407,000 | 0.95% |
| Baker Brothers Advisors | 10,123,824 | $52,846,000 | 0.30% |
| Corton Capital Inc. | 15,586 | $81,000 | 0.08% |
| HHLR ADVISORS, LTD. | 583,333 | $3,045,000 | 0.06% |
| Delphia (USA) Inc. | 16,940 | $88,000 | 0.06% |
| Rock Springs Capital Management LP | 368,959 | $1,926,000 | 0.06% |
| Virtus ETF Advisers LLC | 24,005 | $125,000 | 0.05% |
| CAXTON ASSOCIATES LP | 83,867 | $438,000 | 0.04% |
| GSA CAPITAL PARTNERS LLP | 36,626 | $191,000 | 0.03% |
| PDT Partners, LLC | 43,731 | $228,000 | 0.02% |